Skip to main content

Table 1 Clinicopathologic characteristics and histological analysis

From: Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants

  Total (N = 52) EML4 variants (N = 33) Non-EML4 variants (N = 19) P value
Clinicopathologic parameters
 Age, median (range) 52 (31–76) 50 (31–76) 55 (32–70) 0.227
 Women (%) 29 (55.8) 21 (63.6) 8 (42.1) 0.132
 Smoking history (%) and pack-years     0.904
  Never smoker 35 (67.3) 23 (69.7) 12 (63.2)  
  Ex-smoker, pack-years 6 (11.5), 17.7 4 (12.1), 19.4 2 (10.5), 14.3  
  Current smoker, pack-years 11 (21.2), 23.1 6 (18.2), 19.6 5 (26.3), 27.4  
 Pathologic stage     0.546
  IIIB 3 (5.8) 1 (3.0) 2 (10.5)  
  IV 49 (94.2) 32 (97.0) 17 (89.5)  
 Metastasis sites
  Brain 23 (44.2) 14 (42.4) 9 (47.4) 0.730
  M1a sites 28 (53.8) 22 (66.7)* 6 (31.6) 0.015
  M1b sites 35 (67.3) 22 (66.7) 13 (68.4) 1.000
  M1ab sites 49 (94.2) 32 (97.0) 17 (89.5) 0.546
  Death 19 (36.5) 11 (33.3) 8 (42.1) 0.527
Histologic parameters
 Presence of mucin 10 (22.7) 5 (17.2) 5 (33.3) 0.271
  Intracellular, columnar cells 4 (9.1) 1 (3.4) 3 (20.0) 0.107
  Intracellular, signet ring cells 7 (15.9) 4 (13.8) 3 (20.0) 0.675
  Extracellular 4 (9.1) 1 (3.4) 3 (20.0) 0.107
Predominant pattern     0.443
  Acinar 15 (38.5) 8 (33.3) 7 (46.7)  
  Solid 18 (46.2) 11 (45.8) 7 (46.7)  
  Cribriform 4 (10.3) 4 (16.7) 0 (0.0)  
  Micropapillary 2 (5.1) 1 (4.2) 1 (6.7)  
 Cribriform pattern 10 (22.7) 7 (24.1) 3 (20.0) 1.000
 Solid signet rings 25 (56.8) 17 (58.6) 8 (53.3) 1.000
 Prominent nucleoli 17 (38.7) 14 (48.2) 3 (20.0) 0.136
 Psammomatous calcification 6 (13.6) 4 (13.8) 2 (13.3) 1.000
  1. EML4-ALK variant 1 (N = 13, 65.0 %); EML4-ALK variant 2 (N = 1, 33.3 %); EML4-ALK variant 3a/b (N = 8, 80.0 %)